Regeneron (REGN) Q1 2026 earnings review
Top-Line Power Masks Gross Margin and Earnings Headwinds
Regeneron delivered an impressive 19% top-line acceleration to $3.6 billion, driven by unstoppable momentum from Dupixent and Libtayo. However, management's narrative of double-digit bottom-line growth relies heavily on non-GAAP adjustments. In reality, GAAP Net Income fell 10% YoY to $727 million. The culprit: a 500-basis-point compression in GAAP gross margin due to a manufacturing interruption at the Limerick facility, compounded by a spike in acquired IPR&D expenses. Meanwhile, the EYLEA franchise transition is entering its most critical phase, with high-dose EYLEA HD nearly crossing over standard EYLEA sales in the U.S., but total franchise revenue remains in a decelerating trend.
🐂 Bull Case
Global Dupixent sales surged 33% YoY to $4.9 billion, and Libtayo revenue accelerated 54% to $438 million. These assets are successfully offsetting the revenue bleed from the legacy EYLEA business.
EYLEA HD U.S. net sales grew 52% YoY to $468 million. While sequentially lower than Q4, physician unit demand actually increased 10% QoQ when stripping out prior-quarter inventory noise.
🐻 Bear Case
An unanticipated manufacturing halt at the Limerick facility crushed GAAP gross margins (76% vs 81% YoY) and forced a full-year guidance cut. This adds to existing third-party manufacturing headaches.
Despite the HD ramp, total U.S. EYLEA franchise sales decelerated by 10% YoY to $941 million as standard EYLEA sales collapsed 36% under competitive pressure.
⚖️ Verdict: ⚪
Neutral. The pipeline and oncology/immunology portfolios are firing on all cylinders, but manufacturing stumbles, unabsorbed overhead costs, and the persistent decline of the total EYLEA franchise limit near-term upside.
Key Themes
Immunology & Oncology: The True Growth Engines
Regeneron's reliance on EYLEA is successfully reversing. The Sanofi collaboration revenue (driven by Dupixent profits) accelerated 36% YoY to $1.61 billion. Dupixent continues to secure new approvals, including pediatric CSU and Allergic Fungal Rhinosinusitis. Concurrently, Libtayo global sales grew 54% to $438 million, cementing its role as a key pillar in the oncology portfolio.
Limerick Facility Disruption Crushes Margins
A major operational red flag emerged: a temporary interruption at the bulk manufacturing facility in Limerick, Ireland. This resulted in unabsorbed manufacturing costs and elevated inventory write-offs, driving GAAP gross margin down to 76% from 81% a year ago. While initial production has resumed, management warned margins will remain pressured through Q2.
EYLEA HD Pre-filled Syringe Purgatory
The regulatory saga for the EYLEA HD pre-filled syringe (PFS) drags on. The FDA missed the April PDUFA date for the second contract manufacturer, while the Catalent Indiana site application remains pending following a recent re-inspection. Until the PFS is approved, EYLEA HD is competing with one hand tied behind its back regarding physician convenience.
Macro Truce: The U.S. Government Pricing Agreement
In a major strategic maneuver, Regeneron reached an agreement with the U.S. government to offer Medicaid Most-Favored-Nation pricing and direct patient purchase options for Praluent. In exchange, the company secured a three-year tariff relief window and immunity from future pricing mandates, removing a massive regulatory overhang from the stock.
Genetic Medicine Validated: Otarmeni Approval
Regeneron proved its genetic medicine capabilities with the accelerated FDA approval of Otarmeni (lunsotogene parvec), the first in vivo gene therapy for genetic hearing loss (OTOF variants). While the company plans to provide it for free in the U.S. (meaning zero near-term revenue), it structurally validates the clinical technology platform.
Other KPIs
Management heavily promoted a 15% increase in non-GAAP EPS, but this contradicts the reality of the GAAP bottom line, which fell 10% YoY. The divergence was driven by the Limerick facility manufacturing hit ($92M adjustment) and a surge in acquired IPR&D to $102M (up from $12M), largely reflecting equity premiums and collaboration milestones.
Capital returns remain stable. Regeneron repurchased $803 million in stock during Q1, leaving $688 million on the prior authorization. The Board authorized a massive new $3.0 billion program, signaling long-term confidence despite near-term gross margin compression.
Guidance
Decelerating. Lowered from the prior guide of 79%-80%. This directly reflects the financial damage from the Limerick facility shutdown. Non-GAAP gross margin was left unchanged at 83%-84% as management strips out the temporary manufacturing interruption costs.
Stable. Unchanged from prior guidance, representing a massive reinvestment of capital into the ~50 clinical programs, particularly late-stage assets in oncology (fianlimab) and hematology/thrombosis.
Accelerating slightly. The guidance floor and ceiling were raised by $15 million, explicitly to account for the temporary manufacturing interruption costs shifting into collaboration expense lines.
Key Questions
Limerick Facility Impact
What is the specific root cause of the facility repairs at Limerick, and what gives you confidence that production levels will normalize by the end of Q2 without compromising long-term supply safety stock?
EYLEA HD PFS Timeline
With the FDA missing the action date on the alternate manufacturer and Catalent undergoing re-inspection, what is the realistic worst-case scenario for the Pre-Filled Syringe approval, and how does that alter your internal conversion forecasts?
Fianlimab Pipeline Status
Phase 2 data in first-line advanced NSCLC did not support advancement to Phase 3. Does this change your confidence or statistical assumptions for the upcoming Phase 3 melanoma readout in Q2?
Government Pricing Truce Economics
Regarding the new agreement with the U.S. government on Most-Favored-Nation pricing for Medicaid: what is the modeled net financial impact of the pricing concessions versus the savings gained from the three-year tariff relief?